European Journal

Genetic Technologies Provides Business Update

Retrieved on: 
星期三, 一月 11, 2023
Insurance, Associate, Cardiovascular disease, VSR, BIM, E-commerce, Type 2 diabetes, Face, Ovarian cancer, Interview, PLOS, Personalized medicine, DNA, ROI, Degenerative disease, Hospital, Risk, European Journal, Health, Medical Affairs Bureau, NIPT, Affinity, News, NATA, Growth, ASX, Patient, GTG, Paternity, Journal, Genetypes, CVD, Royal, Breast cancer, Physician, Farm, Agriculture, Pharmaceutical industry, Health insurance, Medical imaging, Medical device, Aquaculture

MELBOURNE, Australia, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE,”Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to provide the following business update for the first half of the 2023 financial year.

Key Points: 
  • MELBOURNE, Australia, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE,”Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to provide the following business update for the first half of the 2023 financial year.
  • Our portfolio features the most comprehensive genetic solutions for the modern medical challenges.
  • The Company’s geneType tests are underpinned by 27 patents, 18 of which are granted patents, protecting geneType sales in key markets.
  • Authorised for release by the board of directors of Genetic Technologies Limited.

Preventing Strokes and Heart Attacks Doesn't Have to Come with the Risk of Life-threatening Bleeding

Retrieved on: 
星期日, 十二月 18, 2022
Anticoagulant, Cardiovascular disease, European Journal, Bleeding, Embolism, Infarction, Stroke, Hospital, Pharmacology, ProAc, Holy Grail, Death, Medicinal chemistry, Verseon, Thrombin, Disability, Research, Disease, Cancer, European Journal of Medicinal Chemistry, Patient, Pharmaceutical industry

Hundreds of millions of patients worldwide need anticoagulants to prevent clots that lead to life-threatening events like strokes, heart attacks, and pulmonary embolisms.

Key Points: 
  • Hundreds of millions of patients worldwide need anticoagulants to prevent clots that lead to life-threatening events like strokes, heart attacks, and pulmonary embolisms.
  • Developing drugs that prevent unwanted clots while preserving the body's ability to stop excessive bleeding is the "Holy Grail" of anticoagulant drug programs.
  • Verseon is developing a new generation of anticoagulants called PROACs (Precision Oral Anticoagulants) that address this significant unmet medical need.
  • Verseon also has a second anticoagulant development candidate, VE-2851, which is expected to enter clinical trials at a later date.

Proactive news headlines including Alligator Energy, Horizon Minerals, AuKing Mining and Hygrovest Ltd

Retrieved on: 
星期二, 十二月 13, 2022
Well, Lithium, Acquisition, Electronics, Electricity, Marketing, Tin, ASH, Mineral, IPO, HRZ, JSE, HMI, Sempra Metals Ltd v IRC, Nuclear medicine, RAD, KWR, European Journal of Nuclear Medicine and Molecular Imaging, Health, Hanns, FDA, Copper, IXR, OZM, PXS, HER2, Molecular imaging, Proactivity, RMI, Uranium, TSX, Society, ORN, Conference, Artificial intelligence, European Journal, Collection, ASX, SOR, AAM, CRR, University, Lac Minerals Ltd v International Corona Resources Ltd, REE, Battle of El Bramadero, HGV, OTC, IP PBX, MRE, Gold, Metal, Atmosphere, STM, NFT, Rare-earth element, Mining, Oil, NSW

Click here

Key Points: 
  • Click here
    Lightning Minerals Ltd (ASX:L1M) has identified multiple pegmatite intrusion outcrops across its exploration licences at the Dundas Project in Western Australia.
  • Click here
    Green Critical Minerals Ltd (ASX:GCM) (formerly Chase Mining Corporation Ltd) has appointed Christopher Whiteley to the role of sales and marketing advisor for the McIntosh Project.
  • Click here
    Resource Mining Corporation Ltd (ASX:RMI) will be led by new CEO Andrew Nesbitt from January 16, 2023.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.

Amphera Announces Clinical Updates of MesoPher Cell Therapy

Retrieved on: 
星期一, 十二月 12, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Recurrence, CT, European Journal, Patient, Cancer, OS, Injection, Nominal interest rate, Mesothelioma, BSC, Reactive, Neoplasm, Pancreatic cancer, Pharmaceutical industry

Amphera B.V., a late-stage biotechnology company developing MesoPher cell therapy to treat cancer, today reports topline results from both the phase II Reactive trial and the phase II/III DENIM trial.

Key Points: 
  • Amphera B.V., a late-stage biotechnology company developing MesoPher cell therapy to treat cancer, today reports topline results from both the phase II Reactive trial and the phase II/III DENIM trial.
  • In the phase II Reactive trial, patients with resected pancreatic cancer who had completed standard-of-care chemotherapy received 3 bi-weekly injections of Ampheras MesoPher dendritic cell therapy and booster injections at 4 and 7 months.
  • Further randomized clinical research with MesoPher in pancreatic cancer is a likely next step.
  • MesoPher is comprised of autologous dendritic cells loaded with PheraLys, a lysate of tumour cell lines.

Preventing Strokes and Heart Attacks Doesn't Have to Come with the Risk of Life-threatening Bleeding

Retrieved on: 
星期三, 十二月 14, 2022
ProAc, Anticoagulant, Verseon, Pharmacology, European Journal, Hospital, Stroke, Patient, Disability, Holy Grail, Research, Death, Cardiovascular disease, Thrombin, Disease, Bleeding, Cancer, Embolism, Infarction, Pharmaceutical industry

FREMONT, Calif., Dec. 14, 2022 /PRNewswire/ -- Verseon is delighted to announce that the European Journal of Medicinal Chemistry has published a paper describing the company's groundbreaking research that led to promising novel drug candidates for cardiovascular disease. Cardiovascular disease is the leading cause of death and disability in the world. Hundreds of millions of patients worldwide need anticoagulants to prevent clots that lead to life-threatening events like strokes, heart attacks, and pulmonary embolisms.

Key Points: 
  • Hundreds of millions of patients worldwide need anticoagulants to prevent clots that lead to life-threatening events like strokes, heart attacks, and pulmonary embolisms.
  • Developing drugs that prevent unwanted clots while preserving the body's ability to stop excessive bleeding is the "Holy Grail" of anticoagulant drug programs.
  • Verseon is developing a new generation of anticoagulants called PROACs (Precision Oral Anticoagulants) that address this significant unmet medical need.
  • Verseon also has a second anticoagulant development candidate, VE-2851, which is expected to enter clinical trials at a later date.

Windtree Therapeutics Reports Third Quarter 2022 Financial Results and Provides Key Business Updates

Retrieved on: 
星期一, 十一月 14, 2022
Marketing, Seismology, Late preterm infant, Security (finance), Degenerative disease, Form 10-K, Growth, MD, Treatment, Heart, Instability, Conference, Doctor of Philosophy, Research, Regulation of tobacco by the U.S. Food and Drug Administration, Intellectual property, Wall Street, COVID-19, European Journal, Heart failure, Therapy, Annual report, Respiratory distress syndrome, Maintenance, 1836 U.S. Patent Office fire, Patent, Food, HK, WINT, Hefei, Cardiogenic shock, Republic, Hypertension, AHF, Patient, Pharmaceutical industry, Greater China

WARRINGTON, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, today reported financial results for the third quarter ended September 30, 2022 and provided key business updates.

Key Points: 
  • WARRINGTON, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, today reported financial results for the third quarter ended September 30, 2022 and provided key business updates.
  • The Company had several notable deliverables this quarter and continues to focus on progressing its planned development of istaroxime.
  • With all that we are executing, we look forward to providing our shareholders with updates on our plans and progress.
  • General and administrative expenses for the third quarter of 2022 were $2.7 million, compared to $3.5 million for the third quarter of 2021.

Genetype for Ovarian Cancer Published in Prestigious European Journal of Cancer Prevention

Retrieved on: 
星期三, 十一月 9, 2022
GLOBE, Health, Monash University, Guideline, GTG, Risk, American Cancer Society, Incidence, Death, Diagnosis, Mortality, European Journal, NASDAQ, Genetypes, Science, ASX, Journal, Ovarian cancer, Breast cancer, Woman, UK Biobank, European Journal of Cancer Prevention, Medical device, Birth control

This 10 year prospective cohort study utilizes data from more than 190,000 women and has been published in the prestigious European Journal of Cancer Prevention.

Key Points: 
  • This 10 year prospective cohort study utilizes data from more than 190,000 women and has been published in the prestigious European Journal of Cancer Prevention.
  • Ovarian cancer is one of the top five cancer-associated causes of death in women (American Cancer Society, 2022).
  • GeneType Risk Assessment Test for Ovarian Cancer is able to identify general population women across a spectrum of risk allowing for more nuanced approaches to ovarian cancer screening and risk-reduction.
  • ASX announcement titled: "Journal of Precision Medicine publication confirms GeneType Risk Test outperforms traditional risk assessments for breast cancer".

Plus Therapeutics to Share Data in Oral Presentations from Ongoing ReSPECT™ Clinical Trials at the 35th Annual Congress of the European Association of Nuclear Medicine

Retrieved on: 
星期二, 十月 4, 2022
Perception, Radiation, Congress, Cancer, GLOBE, European Journal of Nuclear Medicine and Molecular Imaging, Association, Nasdaq, Research, Abstract (summary), European Association of Urology, European Journal, Feasibility, Safety, Glioblastoma, Liposome, Neoplasm, PSTV, Therapy, EANM, Molecular imaging, Springer, Patient, Nuclear medicine, EDT, Company, U.S. Securities and Exchange Commission, Pharmaceutical industry

For more information on the EANM Annual Congress visit, https://eanm22.eanm.org/ .

Key Points: 
  • For more information on the EANM Annual Congress visit, https://eanm22.eanm.org/ .
  • Plus Therapeutics, Inc. isa clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases.
  • Our proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology.
  • This press release contains statements that may be deemed forward-looking statements within the meaning of U.S. securities laws.

The Brattle Group Welcomes Competition Economist Dr. Tim Reuter

Retrieved on: 
星期一, 十月 3, 2022
Review, Doctor of Philosophy, Competition, Industrial organization, Economics, Industry, Law, European Journal, European Commission, Multimedia, Brattle Group, University of Konstanz, European Journal of Law and Economics, Diploma, Principal, Publication, University, Directorate-General for Competition, Leadership, Royal commission, News, Medical device, EU

BRUSSELS, Oct. 3, 2022 /PRNewswire/ -- The Brattle Group has welcomed economist Dr. Tim Reuter to its Brussels office as a Principal with the firm's European Antitrust & Competition practice.

Key Points: 
  • BRUSSELS, Oct. 3, 2022 /PRNewswire/ -- The Brattle Group has welcomed economist Dr. Tim Reuter to its Brussels office as a Principal with the firm's European Antitrust & Competition practice.
  • "With his skills and breadth of experience working with the European Commission and national competition authorities, Tim is a welcome addition to Brattle's ever-expanding Europe competition team," said Peter Davis, Principal and Leader of Brattle's European Antitrust & Competition practice.
  • "Brattle has a top-notch competition practice, and I'm excited to be joining such a strong and collaborative team," said Dr. Reuter.
  • Prior to joining Brattle, Dr. Reuter was a Principal at a consulting firm focused on competition economics.

The Brattle Group Welcomes Competition Economist Dr. Tim Reuter

Retrieved on: 
星期一, 十月 3, 2022
Review, Doctor of Philosophy, Competition, Industrial organization, Economics, Industry, Law, European Journal, European Commission, Brattle Group, University of Konstanz, European Journal of Law and Economics, Diploma, Principal, Publication, University, Directorate-General for Competition, Leadership, Royal commission, News, Medical device, EU

BRUSSELS, Oct. 3, 2022 /PRNewswire/ -- The Brattle Group has welcomed economist Dr. Tim Reuter to its Brussels office as a Principal with the firm's European Antitrust & Competition practice.

Key Points: 
  • BRUSSELS, Oct. 3, 2022 /PRNewswire/ -- The Brattle Group has welcomed economist Dr. Tim Reuter to its Brussels office as a Principal with the firm's European Antitrust & Competition practice.
  • "With his skills and breadth of experience working with the European Commission and national competition authorities, Tim is a welcome addition to Brattle's ever-expanding Europe competition team," said Peter Davis, Principal and Leader of Brattle's European Antitrust & Competition practice.
  • "Brattle has a top-notch competition practice, and I'm excited to be joining such a strong and collaborative team," said Dr. Reuter.
  • Prior to joining Brattle, Dr. Reuter was a Principal at a consulting firm focused on competition economics.